The epothilones represent a new class of bacterial natural products with broad spectrum of antiproliferative activity against various types of human tumors and tumor cell lines. The attractive preclinical profile of epothilones has made them promising lead compounds for novel anticancer agents and has spurred a strong interest in obtaining different derivatives to fully evaluate their therapeutic potentials. We have generated a number of novel epothilone D and 10, 11-dehydroepothilone D (Epo490) analogs via biotransformation using Amycolata autotrophica to alter the oxidation state of the parental compounds. The bioconverted compounds displayed different degrees of potency in cytotoxicity assays against a panel of human tumor cell lines, with 11-hydroxyepothilone D, 14-hydroxyepothilone D, and 21-hydroxyepothilone D showing comparable activity to that of epothilone D, and 21-hydroxy Epo490 being comparable to Epo490. The addition of hydroxyl group(s) seems to cause a decrease in cytotoxic activity against multiple drug resistant cell lines (with overexpressed P-glycoprotein). The compounds generated by biotransformation exert differential effects on tubulin polymerization, which correlate with their biological activities.
Epothilones, a new class of macrolactones originally isolated from the soil bacterium Sorangium cellulosum, represent a new class of naturally occurring microtubule depolymerization inhibitors2,3). Epothilones A and B were first identified. The 12, 13-desoxy counterparts of epothilones A and B, also known as epothilones C and D, have been chemically synthesized de novo but also observed in fermentation extracts of S. cellulosum along with a variety of other epothilone-like structures produced as minor constituents1,4,5) Epothilone D is reported to exhibit the highest therapeutic index. Epothilones have great potential for the treatment of cancer. Although structurally dissimilar, the mechanism of action of the epothilone family is similar to the cancer drug paclitaxel (Taxol), involving induction of tubulin polymerization and stabilization of microtubule assembly6,7). These compounds exhibit potent cytotoxic activity against various cancer cell lines. In particular, they display dramatically improved potency against multiple drug resistant (MDR) tumor cell lines that are highly resistant to Taxol and other anticancer drugs8,9). Epothilone D and 21-hydroxyepothilone D have been demonstrated to have curative effects against human tumor xenografts in nude mice9,10) Epothilone B, BMS-24755011) (a derivative of epothilone B) and epothilone D are currently undergoing clinical trials.
We recently reported the sequence of the epothilone gene cluster and its heterologous expression in Streptomyces coelicolor12) and Myxococcus xanthus13). In both hosts, either epothilones A and B or epothilones C and D were produced as major compounds, depending on whether the epoxidase that converts epothilones C and D to A and B, respectively, was coexpressed with the PKS genes. 10, 11-Dehydroepothilone (Epo490) was isolated as a minor fermentation component from the epothilone D producing strain M. xanthus K111-7213,14) We also constructed a mutant M. xanthus strain, K165-78, from M. xanthus K111-72 to produce Epo490 as a major component14)
The great potential of epothilones in cancer therapy has generated strong interest in novel epothilone analogs. In this study, we used the microorganism Amycolata autotrophica to alter the oxidation state of epothilone D and Epo490 to generate analogs. The analogs include novel compounds, some with potent cytotoxic activity. 
Purification of Bioconverted Products
The biotransformation culture was vigorously mixed with 2 volumes of ethyl acetate and the mixture was filtered through a bed of Celite 521 (Aldrich Chemicals Co.). The filtrate was transferred to a separating funnel, and the upper organic phase was concentrated to dryness on a rotary evaporator to give a crude extract. The crude extract was then subjected to column chromatography, eluting with 10%, 20%, 30%, 40% and 50% of acetone in hexane. After TLC analysis (50% acetone in hexane), five pools were collected, evaporated and subjected to HPLC using a C-18 
Bioconverted Epothilone Analogs Display
Tumor Cytotoxic Activity
To determine the biological activity of the bioconverted compounds, cytotoxicity assays were carried out on a panel of human cancer cell lines derived from breast, lung and central nervous system tumors. Table 1 Our studies showed that the addition of a hydroxyl group lowered the cytotoxic activity against NCI/ADR-RES cells with MDR phenotypes that overexpress P-glycoproteins. This observation is consistent with a recent report in which the chemically synthesized 21-hydroxyepothilone D exhibited marked increases in IC50s ranging from about 5 to 34 fold in five of the ten MDR-resistant cell lines examined10). It is possible that hydroxylation makes these compounds better substrates of the p-glycoprotein pumps in those cells. In this regard, the cytotoxicity of the hydroxylated compounds should be tested in MDR cells without overexpression of p-glycoprotein. Nevertheless, because compound 4 is very active against some MDR cell lines, it is likely that other hydroxylated compounds, such as compounds 1 and 2, may also have the same property.
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